2 companies in Longevity, publicly listed.
Longeveron
Longevity · Regeneration · Cell therapy for ageing-related and other conditions
Latest (Oct 26, 2026): Longeveron Announces Updated Results from ELPIS II Phase 2b Clinical Trial Evaluating Laromestrocel as a Potential Treatment for Hypoplastic Left Heart Syndrome (HLHS)
Open profile →BioAge Labs
Longevity · Drug development informed by the biology of ageing
Latest (Aug 5, 2026): BioAge Labs Reports Second Quarter 2026 Financial Results and Provides Business Updates
Open profile →Coverage is not an offer to invest. Private ownership does not imply available shares. Sector labels are Sapien Frontier’s own coverage classification, not company claims.
Missing a company? Request future coverage. We add a company when its filings, offering notices or awards can be followed reliably. See what we cover and how often.